MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy

The FDA has publicly released its August 2024 Complete Response Letter, denying approval for Lykos Therapeutics' MDMA-assisted therapy for Posttraumatic Stress Disorder (PTSD). MAPS Founder Rick Doblin criticized the FDA, asserting it "moved the goalposts" on trial standards, particularly regarding double-blind studies, after initially approving the Phase 3 protocol. This rejection delays a potentially critical treatment for 13 million Americans with PTSD, though Lykos plans to continue negotiations and MAPS remains committed to advancing psychedelic-assisted therapies.

Analysis

The public release of the FDA's Complete Response Letter (CRL) for Lykos Therapeutics' MDMA-assisted therapy confirms a significant regulatory setback for the psychedelic medicine sector. According to MAPS Founder Rick Doblin, the rejection stems from the FDA retroactively changing its standards for trial design, specifically regarding the challenges of conducting double-blind studies, after the Phase 3 protocol had been established via a Special Protocol Assessment in 2017. This assertion that the FDA "moved the goalposts" introduces a material uncertainty for other companies in the space, suggesting that prior agreements on trial design may not be binding. The decision delays a potential treatment for an estimated 13 million Americans with PTSD. While Lykos Therapeutics intends to continue negotiations with the agency, the strongly negative and defensive tone of the MAPS statement indicates a deep division between developers and regulators, which could prolong the path to any potential resubmission and approval.

Key Decisions for Investors

• Investors should increase their risk premium for the psychedelic medicine sector, as the FDA's rejection highlights significant, and potentially shifting, regulatory hurdles regarding clinical trial design, particularly the integrity of double-blind protocols.
• Re-evaluate competing firms in the mental health space; this delay for a leading MDMA therapy may create a relative advantage for companies developing alternative PTSD treatments or those with psychedelic trial designs that more robustly address the FDA's apparent concerns about blinding.
• Closely monitor the outcome of Lykos Therapeutics' negotiations with the FDA, as any requirements for new data or revised trial protocols will set a critical precedent and provide insight into the viable regulatory pathway for the entire industry.